Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of YK-1169 versus ceftazidime-avibactam for carbapenem-resistant Gram-negative cIAI or BSI
CTR20250851Phase 3Active
- Sponsor
- Nanjing Libowei Pharmaceutical
- Start
- Mar 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cefepime + avibactam in Intra-abdominal infection (IAI), bloodstream infection (BSI), sponsored by Nanjing Libowei Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
cefepime + avibactam
03
Conditions
Intra-abdominal infection (IAI)bloodstream infection (BSI)
Beyond the preview
Go deeper on CTR20250851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250851.